STOCK TITAN
  1. Home
  2. News
  3. CYCCP

Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock - CYCCP STOCK NEWS

Welcome to our dedicated page for Cyclacel Pharmaceuticals 6% Cnvrtbl. Prfrd. Stock news (Ticker: CYCCP), a resource for investors and traders seeking the latest updates and insights on Cyclacel Pharmaceuticals 6% Cnvrtbl. Prfrd. Stock stock.

Cyclacel Pharmaceuticals Inc., located in London, UK, is a clinical-stage biopharmaceutical company focused on developing targeted medicines for cancer and other proliferative diseases. Specializing in CDK and PLK inhibitors, Cyclacel is dedicated to advancing pipeline programs like fadraciclib, Sapacitabine, and plogosertib to combat cancer effectively.

News

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) has regained compliance with Nasdaq Listing Rule 5250(c)(1) by filing its quarterly report on Form 10-Q for the period ended September 30, 2023, on November 29, 2023. The Nasdaq Stock Market LLC has closed the matter, indicating positive regulatory compliance for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
News

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. (CYCC, CYCCP) received a notice of non-compliance from Nasdaq for not filing its quarterly report on time, impacting its compliance with Nasdaq Listing Rule 5250(c)(1). The company has until January 20, 2024, to submit a plan to regain compliance and until May 20, 2024, to actually regain compliance, with no immediate effect on its securities' listing or trading.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) expects to release updated Phase 1/2 clinical and biomarker data for oral Fadraciclib and provide safety, efficacy, and mechanism update for oral Plogosertib. The company reported third quarter financial results, including cash equivalents of $5.9 million as of September 30, 2023, and net loss of $6.1 million for the same period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.89%
Tags
earnings
News

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. will release its third quarter 2023 financial results on November 13, 2023, and host a conference call and live webcast the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
earnings
-
News

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. announces Q2 financial results and business update. Expects to release Phase 1/2 data for oral Fadraciclib and signals of single-agent efficacy for oral Plogosertib. Cash equivalents at $10.2 million. Available cash to fund planned programs through end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
earnings
-
News

Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

Rhea-AI Summary
Cyclacel Pharmaceuticals will announce its second quarter 2023 financial results on August 9, 2023. The company will host a conference call and live webcast on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
earnings
News

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.75%
Tags
earnings
-
News

Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
News

Cyclacel Pharmaceuticals to Participate in March Investor Conferences

Rhea-AI Summary

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced its participation in two upcoming investor conferences. The Oppenheimer 33rd Annual Healthcare Conference will be held virtually from March 13-15, 2023, featuring a fireside chat on March 13 at 10:00 am ET led by Spiro Rombotis. The 35th Annual Roth Conference takes place in Dana Point, CA from March 12-14, 2023, with a fireside chat on March 13 at 3:00 pm PT presented by Paul McBarron. Cyclacel is focused on developing innovative cancer treatments targeting cell cycle and transcriptional regulation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
conferences

FAQ

What is the current stock price of Cyclacel Pharmaceuticals 6% Cnvrtbl. Prfrd. Stock (CYCCP)?

The current stock price of Cyclacel Pharmaceuticals 6% Cnvrtbl. Prfrd. Stock (CYCCP) is $6.47 as of December 23, 2024.

What is the market cap of Cyclacel Pharmaceuticals 6% Cnvrtbl. Prfrd. Stock (CYCCP)?

The market cap of Cyclacel Pharmaceuticals 6% Cnvrtbl. Prfrd. Stock (CYCCP) is approximately 12.3M.

What is Cyclacel Pharmaceuticals Inc. known for?

Cyclacel is known for developing targeted medicines for cancer and other proliferative diseases.

Where is Cyclacel Pharmaceuticals Inc. located?

The company is located in London, United Kingdom.

What are the core focus areas of Cyclacel Pharmaceuticals Inc.?

Cyclacel focuses on CDK and PLK inhibitors for cancer treatment.

What are some of the pipeline programs of Cyclacel Pharmaceuticals Inc.?

Some pipeline programs include fadraciclib, Sapacitabine, and plogosertib.

What is the mission of Cyclacel Pharmaceuticals Inc.?

The mission is to develop innovative medicines to combat cancer effectively.

How does Cyclacel Pharmaceuticals Inc. contribute to the biopharmaceutical industry?

Cyclacel contributes through its research and development of targeted cancer treatments.

What sets Cyclacel Pharmaceuticals Inc. apart from other biopharmaceutical companies?

Cyclacel's focus on CDK and PLK inhibitors distinguishes it in the industry.

What recent achievements has Cyclacel Pharmaceuticals Inc. made?

Cyclacel has made progress in advancing their pipeline programs for cancer treatments.

Are there any partnerships associated with Cyclacel Pharmaceuticals Inc.?

Cyclacel may have partnerships with other companies for research and development collaborations.

How can I stay updated with the latest news from Cyclacel Pharmaceuticals Inc.?

Visit their official website or follow their press releases for the most recent updates.

Stock CYCCP logo
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock

Nasdaq:CYCCP

CYCCP Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CYCCP Stock Data

12.30M
333.67k
0.48%
0.03%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BERKELEY HEIGHTS